For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 44,923 | |||
| General and administrative | 12,693 | |||
| Total operating expenses | 57,616 | |||
| Loss from operations | -57,616 | |||
| Other income, net | 1,772 | |||
| Net loss | -55,844 | |||
| Unrealized gain on marketable securities | 17 | |||
| Total comprehensive loss | -55,827 | |||
| Basic EPS | -19.65 | |||
| Diluted EPS | -19.65 | |||
| Basic Average Shares | 2,842,448 | |||
| Diluted Average Shares | 2,842,448 | |||
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)